Explores how maternal opioid use and hepatitis C affect immune function in pregnant individuals, suggesting important health implications.
This study was supported by grants from the National Institutes of Health: 1R01DA059152-01 (IM and JO), 7R01AI145910-05S1(IM), TL1TR001997 (HT) and pilot funding from the University of Kentucky, including the Clinical and Translational Science Substance Use Disorder pilot grant 3210003238 (IM and JO). This research was indirectly supported by the Kentucky Opioid Response Effort (KORE) via Substance Abuse and Mental Health Services Administration (SAMHSA) Grants, H79TI081704, H79TI083283, as well as the data management system that is hosted by UK with grant support from NIH CTSA UL1TR001998. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the University of Kentucky.
No takes yet. Share an insight, caveat, or question.
Doratt et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: